BrainsWay Presentations & Investor Relations material

BrainsWay is a leading global neurmodulation company with headquarters in Jerusalem and the US. Our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. A non-invasive, yet highly effective solution for brain disorders, BrainsWay has helped thousands of patients across the world, from the Unites States to Europe to South America, and has the potential to make a difference in the well-being and health of millions of patients worldwide. BrainsWay's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. BrainsWay's treatment has FDA approval for treating patients with Major Depressive Disorder*. The technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. In addition to being used to treat depression daily across the world, BrainsWay's technology has been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. BrainsWay technology is based on a patent registered by the U. S. National Institutes of Health (NIH). BrainsWay is dedicated to research and continuously explores treatments for a variety of brain disorders.* The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. 122888